Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: A retrospective comparison of miriplatin and epirubicin

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 113-119

  Iwazawa, Jin ^a   Ohue, Shoichi ^b   Hashimoto, Naoko ^a   Mitani, Takashi ^a  

^a NISSAY HOSPITAL   (Japan)

^b Komatsu Hospital   (Japan)

Author keywords

Chemoembolization; Epirubicin; Liver; Miriplatin; Neoplasms

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MIRIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROTEIN BLOOD LEVEL; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR GROWTH;

EID: 84861135851     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S30431     Document Type: Article

References (21)

1. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224(1):47-54.
2. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429-442.
3. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989; 170(3 Pt 1):783-786.
4. Okusaka T, Okada S, Nakanishi T, Fujiyama S, Kubo Y. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs. 2004;22(2):169-176.
5. Maeda M, Uchida NA, Sasaki T. Liposoluble platinum(II) complexes with antitumor activity. Jpn J Cancer Res. 1986;77(6):523-525.
6. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull. 2000;23(3):344-348.
7. Hanada M, Baba A, Tsutsumishita Y, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64(3):473-483.
8. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci. 2009;100(1):189-194.
9. Okusaka T, Kasugai H, Ishii H. SM-11355 Japan study group. a randomized phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in comparison with zinostatin stimalamer in patients with hepatocellular carcinoma. J Clin Oncol. 2009;27 Suppl:abstr 4853.
10. Okabe K, Beppu T, Haraoka K, et al. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res. 2011;31(9):2983-2988.
11. Imai N, Ikeda K, Seko Y, et al. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology. 2011;80(3-4): 188-194.
12. Imai Y, Chikayama T, Nakazawa M, et al. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol. October 6, 2011. [Epub ahead of print.]
13. Takayasu K, Muramatsu Y, Maeda T, et al. Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol. 2001;176(3):681-688.
14. Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-F tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol. 2007;18(3):365-376.
15. Miyayama S, Yamashiro M, Shibata Y, et al. Comparison of local control effects of superselective transcatheter arterial chemoembolization using epirubicin plus mitomycin C and miriplatin for hepatocellular carcinoma. Jpn J Radiol. January 7, 2012. [Epub ahead of print.]
16. Ono Y, Yoshimasu T, Ashikaga R, et al. Long-term results of lipiodoltranscatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol. 2000;23(6): 564-568.
17. Doroshow JH, Locker GY, Myers CE. Experimental animal models of adriamycincardiotoxicity. Cancer Treat Rep. 1979;63(5):855-860.
18. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer. 1989;64(8):1586-1594.
19. Iwazawa J, Ohue S, Yasumasa K, Mitani T. Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver. World J Radiol. 2010;2(12):468-471.
20. Hanada M, Takasu H, Kitaura M. Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis. Oncology Rep. 2010;24(4):1011-1018.
21. Kawaoka T, Aikata H, Katamura Y, et al. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21(8):1219-1225.